Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Current Opinion in Immunology
|
March 8, 2013
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
Michel DuPage, Tyler Jacks
Cancer Immunology Research
|
November 15, 2023
Separating the Good from the Bad: Tumor-Infiltrating Tregs Have Increased Fucosylation
Stephanie Silveria, Michel DuPage
Nature Reviews. Immunology
|
February 16, 2016
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease
Michel DuPage, Jeffrey A Bluestone
Cancer Cell
|
June 11, 2024
Breaking up the CD8<sup>+</sup> T cell: Treg pas de deux
Chenyu Zhang, Alissa Bockman, Michel DuPage
Nature Protocols
|
June 30, 2009
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Michel DuPage, Alison L Dooley, Tyler Jacks
Immunology
|
March 14, 2019
Treg programming and therapeutic reprogramming in cancer
Mariela A Moreno Ayala, Zehui Li, Michel DuPage
Nature
|
February 10, 2012
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage, Claire Mazumdar, Leah M Schmidt, et al.
Cell Reports
|
September 12, 2024
Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation
Janneke G C Peeters, Stephanie Silveria, Merve Ozdemir, et al.
Biorxiv : the Preprint Server for Biology
|
April 22, 2024
Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation
Janneke G C Peeters, Stephanie Silveria, Merve Ozdemir, et al.
Biorxiv : the Preprint Server for Biology
|
September 15, 2025
Epigenetically regulated p53 activity maintains intestinal regulatory T cell identity to prevent inflammation
Stephanie Silveria, Janneke Gc Peeters, Jenna Vickery, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Current Opinion in Immunology
|
March 8, 2013
Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response
Michel DuPage, Tyler Jacks
Cancer Immunology Research
|
November 15, 2023
Separating the Good from the Bad: Tumor-Infiltrating Tregs Have Increased Fucosylation
Stephanie Silveria, Michel DuPage
Nature Reviews. Immunology
|
February 16, 2016
Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease
Michel DuPage, Jeffrey A Bluestone
Cancer Cell
|
June 11, 2024
Breaking up the CD8<sup>+</sup> T cell: Treg pas de deux
Chenyu Zhang, Alissa Bockman, Michel DuPage
Nature Protocols
|
June 30, 2009
Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase
Michel DuPage, Alison L Dooley, Tyler Jacks
Immunology
|
March 14, 2019
Treg programming and therapeutic reprogramming in cancer
Mariela A Moreno Ayala, Zehui Li, Michel DuPage
Nature
|
February 10, 2012
Expression of tumour-specific antigens underlies cancer immunoediting
Michel DuPage, Claire Mazumdar, Leah M Schmidt, et al.
Cell Reports
|
September 12, 2024
Hyperactivating EZH2 to augment H3K27me3 levels in regulatory T cells enhances immune suppression by driving early effector differentiation
Janneke G C Peeters, Stephanie Silveria, Merve Ozdemir, et al.
Biorxiv : the Preprint Server for Biology
|
April 22, 2024
Increased EZH2 function in regulatory T cells promotes their capacity to suppress autoimmunity by driving effector differentiation prior to activation
Janneke G C Peeters, Stephanie Silveria, Merve Ozdemir, et al.
Biorxiv : the Preprint Server for Biology
|
September 15, 2025
Epigenetically regulated p53 activity maintains intestinal regulatory T cell identity to prevent inflammation
Stephanie Silveria, Janneke Gc Peeters, Jenna Vickery, et al.
Page
of 4